186 related articles for article (PubMed ID: 22233211)
1. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
Li C; Shen J; Wei X; Xie C; Lu W
J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
[TBL] [Abstract][Full Text] [Related]
2. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
4. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
6. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
8. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
9. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery.
Zhan C; Meng Q; Li Q; Feng L; Zhu J; Lu W
Chem Asian J; 2012 Jan; 7(1):91-6. PubMed ID: 22072592
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W
J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115
[TBL] [Abstract][Full Text] [Related]
11. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
12. Polyethylene glycol-polylactic acid nanoparticles modified with cysteine-arginine-glutamic acid-lysine-alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect.
Wu J; Zhao J; Zhang B; Qian Y; Gao H; Yu Y; Wei Y; Yang Z; Jiang X; Pang Z
Int J Nanomedicine; 2014; 9():5261-71. PubMed ID: 25419130
[TBL] [Abstract][Full Text] [Related]
13. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes.
Yang Y; Yan Z; Wei D; Zhong J; Liu L; Zhang L; Wang F; Wei X; Xie C; Lu W; He D
Nanotechnology; 2013 Oct; 24(40):405101. PubMed ID: 24029287
[TBL] [Abstract][Full Text] [Related]
14. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
15. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
16. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
17. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide.
Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z
Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368
[TBL] [Abstract][Full Text] [Related]
19. Factors Influencing the Immunogenicity and Immunotoxicity of Cyclic RGD Peptide-Modified Nanodrug Delivery Systems.
Wang X; Meng N; Wang S; Lu L; Wang H; Zhan C; Burgess DJ; Lu W
Mol Pharm; 2020 Sep; 17(9):3281-3290. PubMed ID: 32786957
[TBL] [Abstract][Full Text] [Related]
20. Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes.
Wang X; Meng N; Wang S; Zhang Y; Lu L; Wang R; Ruan H; Jiang K; Wang H; Ran D; Zhan C; Yu K; Burgess DJ; Lu W
J Control Release; 2019 Dec; 316():381-392. PubMed ID: 31730912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
